KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Accumulated Expenses (2016 - 2026)

Teva Pharmaceutical Industries filings provide 12 years of Accumulated Expenses readings, the most recent being $555.0 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses rose 17.09% to $555.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $555.0 million, a 17.09% increase, with the full-year FY2025 number at $739.0 million, up 18.43% from a year prior.
  • Accumulated Expenses hit $555.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $739.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $739.0 million in Q4 2025 to a low of $432.0 million in Q1 2023.
  • Median Accumulated Expenses over the past 5 years was $496.0 million (2022), compared with a mean of $533.6 million.
  • Biggest five-year swings in Accumulated Expenses: fell 10.63% in 2022 and later grew 18.43% in 2025.
  • Teva Pharmaceutical Industries' Accumulated Expenses stood at $566.0 million in 2022, then rose by 7.95% to $611.0 million in 2023, then increased by 2.13% to $624.0 million in 2024, then grew by 18.43% to $739.0 million in 2025, then dropped by 24.9% to $555.0 million in 2026.
  • The last three reported values for Accumulated Expenses were $555.0 million (Q1 2026), $739.0 million (Q4 2025), and $561.0 million (Q3 2025) per Business Quant data.